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A gene therapy for cystic fibrosis (CF) lung disease by intralumenal
delivery of therapeutic transgenes into the lung is a logical treat-
ment strategy if efficient gene transfer can be achieved without
detrimental effects to the patient. Indeed, pioneering work in the
late 1980s showed that genetically engineered viruses could deliver
the CF corrective transgene to cultured cells from patients with CF.
However, after many attempts to deliver the corrective gene to the
lungs of patients with CF in vivo and with the luxury of 20/20 hind-
sight, it is realized that although logical, the strategy to accomplish
this task did not appreciate the evolution of the lung to resist invasion
by pathogens such as viruses. It is now apparent that several levels
of barriers exist that restrict exogenous gene delivery to the airway
epithelium by commonly used viral vectors. Components of the
innate and cell-mediated immune system collectively limit both
the access to and duration of gene transfer vectors to the airway
epithelium. Alternative viral vectors that have evolved to circumvent
these barriers will require further development if gene transfer is
ever to be considered a therapy for CF lung disease.
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In this short article, I will sum up experiences of my laboratory
using adenoviral vectors (AdV) as gene delivery vehicles for the
respiratory epithelium, the target tissue for the treatment of the
underlying cause of cystic fibrosis (CF) lung disease. This work
has mainly focused on the “innate” physical and biological barri-
ers posed by the airway epithelium that limit gene transfer effi-
ciency, with the opinion that until efficient gene transfer to the
correct target cells can be achieved the prospect for a safe CF
gene transfer strategy will be limited. This review will discuss
mainly my conclusions from work performed in my laboratory in
the context of work performed by others in the field. Additional
barriers to effective and safe gene transfer such as the host
cellular immune response against vectors and/or transgene anti-
gens and the mechanisms of delivering gene transfer vectors to
the lung will not be discussed here, and the reader is referred
to several recent reviews that address these issues (1, 2).
Several separate scientific advances culminated in the idea that
a gene transfer approach for CF lung disease would be feasible.
Many years of basic research with a common lung virus, the
adenovirus, had generated less pathogenic replication-deficient
vectors capable of expressing a transgene of choice. Secondly,
in 1989, the defective gene that results in CF disease was cloned
and the normal product of this gene identified as a cAMP-
activated chloride ion channel, the cystic fibrosis transmembrane
conductance regulator (CFTR) (3).
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The first signs of CF lung disease occur in the distal bronchio-
lar airways. With time, bronchiolitis and mucus plugging of the
small airways are common findings in the CF lung. The link
between CF pathogenesis and the CFTR defect is related to the
normal function of CFTR maintaining hydration of the pericili-
ary fluid layer that lines the airway surface (4). An absence or
expression of defective CFTR in the lung results in reduced chlo-
ride ion secretion, hyperabsorption of sodium ions, increased vis-
cosity of airway secretions, impaired mucociliary clearance, chronic
bacterial infection, bronchiectasis, and premature death (5). Be-
cause these pulmonary manifestations are likely primary or sec-
ondary to loss of CFTR function, the most efficacious strategy
to treat CF lung disease would be to replace normal CFTR
function in airway epithelial cells, thus “correcting” lung epithe-
lium homeostasis and hopefully lung function.
The airway epithelial cell types that exhibit all of the ion-
and fluid-transporting functions of CFTR and display abnormal
function in patients with CF are the ciliated epithelial cells (6),
which are considered to be the target cell types that require
correction (7, 8). However, immunolocalization studies have
identified the serous cells of the submucosal glands as the highest
CFTR-expressing cell type in the lung, suggesting that these cells
may also be an important target for gene replacement (9).
Shortly after the identification of the CFTR gene, two
groundbreaking observations made gene therapy for CF lung
disease appear imminent. First, isolated epithelial cells derived
from the airway epithelium of patients with CF and cultured on
plastic dishes could be phenotypically “corrected” by transfer-
ring the CFTR cDNA into the cells (10). Secondly, replication-
defective AdV engineered to express the CFTR cDNA were
administered to the airways of experimental animals, and trans-
gene expression was observed in respiratory epithelium (11).
These pioneering studies produced a flurry of scientific activity
and excitement in both the gene therapy and CF scientific com-
munities, and within 3 years of these initial observations the
first clinical trial describing AdV-mediated gene transfer to the
airway epithelium of patients with CF in vivo was reported (12).
Over a decade later, these promising early observations have
unfortunately not withstood further investigation. After over 20
gene therapy clinical trials for CF lung disease (of which greater
than 70% used AdV), the gene therapy community has realized
that gene transfer to airway epithelium in vivo, although logical,
is not trivial. The evolution of the respiratory epithelium as an
effective barrier to invading pathogens entering the lung (e.g.,
viruses), by a host of innate and cell-mediated immune systems,
culminates in restricted cellular uptake of gene transfer vectors
and reduced transgene expression.
VIRAL VECTORS AS GENE DELIVERY VEHICLES TO THE
LUNG: AMBITIOUS OR FAR-SIGHTED?
For most viral vectors proposed over the last 10 years for CFTR
delivery to the lung, the targeting capacity and efficiency of gene
transfer have been rate-limiting to the success of this approach.
The gene transfer efficiency required for physiological correction
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of CF lung disease was first tested by Johnson and colleagues,
who showed in CF cell–mixing experiments that 6 to 10% of
CFTR-expressing cells were required to restore normal levels
of chloride secretory function to an epithelium in vitro (13).
However, this degree of “correction” was insufficient to correct
the hyperabsorption of sodium ions that is likely to be necessary
for resolving CF lung disease. To restore the normal sodium
transporting capabilities of the respiratory epithelium, it has
been hypothesized (but not proven) that greater than 80% of
the surface epithelial cells will have to express CFTR (7). There-
fore, the number of CF cells to be targeted by a vector, i.e.,
ciliated cells, required to express CFTR will be high. Even so,
it must be emphasized that correction of the chloride secretory
defect by replacement of functional CFTR has not yet been
shown to restore ionic homeostasis to the CF lung or reverse
CF-related pathology.
The safety of gene transfer to airway epithelium in vivo using
viral and nonviral vectors in clinical trials has so far been promis-
ing. However, determination of the efficiencies of gene transfer
in the trials performed to date have shown, at best, only partial
“correction” ( 20%) of the CF bioelectrical defect (12, 14–16).
No attempts to determine efficacy of gene transfer on CF lung
disease-related end-points have yet been attempted.
IDENTIFYING AND APPRECIATING THE TARGET
CELL TYPES FOR CFTR DELIVERY IN VIVO
Adenoviral vectors are extremely efficient gene delivery vehicles
once the virus has entered into the target cell. Why then is this
respiratory virus apparently so inefficient at targeting the intact
epithelium in vivo? One consideration when comparing wild-
type adenovirus infection to transduction by AdV is that the
replication-deficient vectors rely on delivering many virus particles
to a target tissue, whereas wild-type virus only requires access to
a small number of cells from which it can propagate and spread
within the target tissue. Replication-competent wild-type Ad may
take advantage of regional differences in airway epithelium integ-
rity and injured epithelium has been shown to be more susceptible
to AdV transduction than intact epithelium (17).
Another misconception about AdV infection of cells was
the correlation of gene transfer efficiency to isolated airway
epithelial cells in vitro to that expected in vivo. The failure of
the lung gene transfer community to appreciate the complex
phenotypic and morphologic characteristics of the target airway
epithelial cells in vivo resulted in trying to “force-feed” viruses
into the target cells without sufficient attempts to understand
the mechanisms that were restricting viral entry into the cell.
Airway epithelial cells are present throughout the conducting
airways of the lung, including the nasal, tracheal, bronchial, and
bronchiolar regions. Airway epithelial cell type composition is
complex because it is species- and airway region–dependent,
and the reader is referred to comprehensive reviews describing
species-specific airway epithelial cell distribution (18, 19). For
the human lung, the conducting airways are composed of several
epithelial cell types dependent on airway region. Generally, the
surface epithelium is composed of ciliated cells, mucus-secreting
cells (goblet), serous cells, Clara cells, and basal cells. Alveolar
regions of the lung consist primarily of alveolar Type I and Type
II cells, although these cell types are not thought to participate
in the pathophysiology of CF lung disease and hence are not
considered targets for CFTR gene transfer.
The lumen of human cartilaginous airways (nasal, tracheal,
and bronchial) is normally lined with a pseudostratified mucocili-
ary epithelium comprised of ciliated cells and mucus-secreting
goblet cells overlying basal epithelial cells (Figure 1). A sub-
subpopulation of basal epithelial cells are considered to be the
stem cell precursors for the ciliated and mucus cell phenotypes
(20). The morphology of the human lower airway epithelium is
distinctly different from the upper airway epithelium, with the
lumen of the bronchiolar regions normally lined with simple
cubiodal ciliated epithelium with few mucus-secreting cells and
no basal cells. Because ciliated epithelial cells are terminally
differentiated and basal epithelial cells are absent from the bron-
chiolar regions, it has been speculated that mucus-producing
cells (Clara cells) may be the progenitors of ciliated cells in these
regions. Overall, it is considered that the ciliated cells in both
upper and lower airway regions are the target cell types for CFTR
gene delivery.
GENE TRANSFER EFFICIENCY TO AIRWAY EPITHELIUM
IS LOW DUE TO CELLULAR BARRIERS TO VIRAL ENTRY
Unlike for isolated airway epithelial cells in vitro, it is now
apparent that there are several extracellular barriers to AdV on
the human airway lumenal surface that result in inefficiency of
gene transfer in vivo (Figure 1). They include the mucociliary
clearance system, the glycocalyceal barrier, the absence of the
adenoviral receptors from the airway lumen, and the slow rate
of lumenal endocytosis of airway epithelial cells (21–23).
A difficulty in the field of CF lung gene transfer has been
identifying a model that recapitulates the phenotypic and mor-
phologic characteristics of the human lung airway epithelium in
vivo. Although mouse models are attractive because they are
inexpensive and can be easily manipulated genetically, the air-
way epithelial cell type distribution in the murine airway (with
the exception of the murine nasal epithelium) is not reflective
of the human. A significant advance in the development of airway
models was the generation of in vitro cell culture models derived
from human primary airway epithelial cells obtained from pa-
tients with or without CF undergoing lung transplantation (22).
Isolated airway epithelial cells grown over a period of 1 to 2
months at an air–liquid interface result in the generation of
a pseudostratified, mucociliary airway epithelium that displays
similar morphologic and phenotypic characteristics of the in
vivo human cartilaginous airway epithelium (Figure 1). Recent
studies have revealed that this model system recapitulates the
phenotypic differences that occur between CF and non-CF air-
way epithelium: cultures from patients with CF display reduced
chloride ion transport, hyperabsorption of sodium ions, the fail-
ure to regulate the depth of airway surface liquid, and the dehy-
dration of secreted mucus that results in cilial dysfunction and
mucostasis (4). Human airway epithelial cell (HAE) culture
models have now been used by a number of different groups to
test the usefulness of viral and nonviral vectors for delivering
genes to the airway epithelium and have been predictive for
gene transfer to human airways in vivo (22, 23).
For example, AdV-mediated gene transfer to airway epithe-
lial cells grown on plastic is highly efficient (24), with cellular
transduction efficiencies of 90 to 100%, and when the transgene
is CFTR, full correction of the spectrum of CF bioelectrical
defects is obtained (25). In contrast, inoculation of the apical
surface of HAE by AdV does not result in efficient gene transfer,
whereas basolateral inoculation is successful at targeting basal
epithelial cells (26). However, columnar epithelial cells including
ciliated cells are susceptible to AdV infection from the lumenal
surface if HAE are inoculated after transient disruption of the
epithelial tight junctions (27) (see below and Figure 2). These
data suggest that the apical surface of polarized respiratory epi-
thelium is restrictive to AdV penetration. These observations
confirmed the earlier data derived from in vivo epithelial cell
models derived from upper airway regions of rodents, nonhuman
primates, and humans that showed that: (1) transgenes were
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Figure 1. Cell type composition of the airway surface epithelium and
potential barriers to gene transfer vectors. (A ) The airway epithelium
is composed of ciliated cells (C), mucus-containing cells (M) overlying
basal epithelial cells (B). Gene transfer vectors delivered via the intralu-
menal route encounter several barriers that may limit gene delivery to
target cells in the airway epithelium: (1 ) secreted mucus; (2 ) structure
and motion of the cilia; (3 ) an airway surface fluid; (4 ) a robust and
structurally diverse glycocalyx; (5 ) an apical membrane that has a lim-
ited endocytotic capacity; and (6 ) epithelial tight junctions that restrict
access to basolateral membranes. (B ) Histological cross-section of a
human airway epithelial cell culture grown at the air–liquid interface
showing ciliated, mucus and basal cell composition. This in vitro model
of the human airway epithelium recapitulates the physical and biological
barriers to gene transfer vectors as seen for the airway epithelium in
vivo. Original magnification: 100 (Richardson’s Stain).
expressed after in vivo dosing in less than 20% of the surface
epithelial cells; and (2) that basal epithelial cells were efficiently
transduced by AdV (17, 24). Subsequently, it was determined
that although both columnar and basal epithelial cells express
the receptors required for AdV entry into cells, the human cox-
sackie B and adenovirus 2 and 5 receptor (hCAR, [28]) and,
v3/5 integrins (29), expression in columnar cells is restricted to
the basolateral domain of the cell membranes (22, 23). In fact,
hCAR has been localized to regions associated with epithelial
cell tight junctions (30), a location that may restrict access of
AdV to hCAR delivered by apical and/or basolateral routes.
This observation may explain why in our hands basolateral inocu-
lation of HAE by AdV failed to efficiently transduce columnar
cell types (Figure 2).
THE GLYCOCALYX AS A RESTRICTION BARRIER FOR
ADV DELIVERY TO THE AIRWAY EPITHELIUM
Because the receptors for AdV cellular entry are localized to
the basolateral compartments of the epithelium and retargeting
Figure 2. Polarized susceptibility of HAE cultures to AdV infection. Con-
focal XZ optical sections of HAE cultures inoculated with AdVGFP and
48 hours later, GFP (green) expression assessed: (A ) Inoculation of the
apical surface of HAE results in low gene transfer efficiency. (B ) Inocula-
tion of the basolateral surface results only in efficient gene transfer to
basal epithelial cells. (C ) Efficient gene transfer to columnar cells after
AdV inoculation of the apical surface immediately after tight junctional
disruption by sodium caprate. Cilia at the apical surface are identified
with anti–-tubulin conjugated to Texas Red (red). Original magnification:
63. Figure reproduced with permission from the Journal of Virology (26).
Figure 3. Restriction of AdV access to the apical membrane of airway
epithelium by the highly glycosylated and abundant glycocalyx. Sche-
matic of the highly glycosylated molecules on the human airway lumenal
surface that comprise the glycocalyx layer. Glycoconjugates such as
tethered mucins (MUC1, MUC4, MUC16) and proteoglycans (PGs)
cover the microvilli-rich airway surface and may attach to and restrict
the access of AdV to the apical membrane. The fate of AdV attached
to these structures may be engulfment by airway macrophages (M)
and/or incorporation into the secreted mucus after shedding of the
glycoconjugate-AdV complex from the apical surface.
strategies are dependent of identification of suitable surrogate
receptors, we investigated whether redistribution of hCAR to
the apical surface of polarized cells would improve the efficiency
of AdV-mediated gene transfer. To achieve this, we expressed
the external domain of hCAR (containing the AdV attachment
site) at the apical surface of polarized epithelia by incorporation
Figure 4. Ciliated cells are infected by RSV and release progeny exclu-
sively from the apical surface. (A ) Cross-section of HAE culture demon-
strating the morphology of the cells at the time of inoculation of the
apical surface by RSV-GFP. (B ) Forty-eight hours later, GFP expression
(green) was seen exclusively in ciliated columnar cells identified by a
cilial specific marker (red). (C ) Long-exposure time image of en face
view of an HAE culture with fluorescent beads incorporated into the
mucus layer showing circular directionality of the mucus layer produced
by coordinated cilial beat. (D ) En face view of an HAE culture infected
with low titer RSV-GFP and 48 hours later, GFP expression assessed.
Circular spread of RSV-GFP infection mirrors that of mucus movement
on the apical surface, suggesting that spread of RSV is facilitated by the
coordinated cilial beat. Original magnification: A and B, 63; C and D,
5. Reproduced in part with permission of the Journal of Virology (26).
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of a glycosylphosphatidylinositol-linker (gpi-hCAR), and found
that although this chimeric receptor was expressed at the apical
membrane, gene transfer efficiency with AdV still remained low.
These studies ultimately identified the lumenal surface glyco-
calyx as another barrier to AdV that functions as a “barbed-wire
fence” to protect the apical surface including apical receptors
from lumenal insult (21). We have now confirmed this barrier
function of the airway glycocalyx to AdV with HAE cultures
and mouse tracheal epithelium in vivo expressing gpi-hCAR
(31). However, the extent of the barrier effect of human airway
glycocalyx in restricting AdV access remains controversial (32).
The glycocalyx on the airway epithelium lumenal surface is
composed of several families of carbohydrate-rich molecules,
including glycoproteins (most notably the mucins), proteogly-
cans, and glycolipids. A major component of the airway glyco-
calyx are the “tethered” mucins, particularly the large ( 1 mega-
dalton), heavily glycosylated MUC1 and MUC4 glycoproteins
(33, 34). With respect to airway gene transfer, sialoglycoconju-
gates (including MUC1) expressed on the apical surface of polar-
ized epithelial cells inhibit AdV-mediated gene transfer (35).
Several mucin species will also be present in the mucus in the
airway lumen and may act as false attachment sites for AdV
thus effectively reducing the amount of AdV that ultimately
reaches the apical surface receptors required for viral penetra-
tion (Figure 3).
The fate of AdV bound to airway glycocalyx components is
speculative. One possibility is that mucins may passively or ac-
tively “present” the bound AdV for recognition and engulfment
by resident airway macrophages. It has been shown in the murine
airway that early after AdV administration to the lung, macro-
phages migrate to and internalize AdV that are present in the
airway lumen possibly attached to glycocalyx structures (36). It
has been estimated that 70 to 90% of AdV are sequestered by
airway macrophages 24 hours after intraluminal administration
to the lung (37). We predict that glycocalyx components present
AdV to incoming macrophages for phagocytosis and degrada-
tion. In addition, tethered mucins are shed from the airway surface
and incorporate into the soluble mucin layers (34). This property
of airway mucins raises the possibility that AdV attached to shed
tethered mucins may be eliminated from airways by incorporation
into the mucociliary transport system.
OVERCOMING THE LIMITATIONS OF LOW EFFICIENCY
OF AdV-MEDIATED GENE TRANSFER
To date, two main strategies to improve the efficiency of gene
transfer of AdV after intralumenal delivery have been attempted.
One approach is to retarget AdV to nonviral receptors present
on the apical surface of lumenal epithelial cells. The other strat-
egy attempts to access the basolateral surfaces of the epithelial
cells either by nonlumenal delivery of vector or by disruption
of epithelial “tight” junctions.
Retargeting AdV to Apical Receptors to Increase Gene
Transfer Efficiency
Retargeted AdV can successfully transduce cell types that are
usually refractory to AdV infection due to lack of attachment/
entry receptors. The epidermal growth factor receptor, stem cell
factor receptor, fibroblast growth factor receptor, V integrins,
and T cell receptors (CD 3) have all been used as surrogate
receptors for AdV entry in a variety of cell types (38–40).
Retargeting AdV to receptors on the airway lumen required
identification of suitable receptors on the target ciliated cells
that are conducive for AdV attachment and entry. Examples of
such receptors are members of the 7-transmembrane spanning
G protein–coupled receptor family (i.e., P2Y2 purinoceptors,
B2-kinin receptors, and adenosine type 2b receptors). These
receptors were identified as putative utile target receptors for
redirecting AdV tropism to the surface epithelium of the lung
because they are highly expressed on the luminal surface and
are internalized into cells upon activation (41). Other receptors
proposed as targets for redirecting gene transfer vectors are
the urokinase plasminogen activator receptor and the SEC-2
receptor (42, 43).
Retargeting of AdV has so far been achieved by chemically,
immunologically, or genetically modifying the AdV capsid coat
by incorporating new receptor ligands that can target candidate
receptors. As a “proof of concept” study, an hemaggluttin (HA)-
epitope tagged P2Y2 receptor expressed at the apical surface
of HAE was targeted with bi-specific antibodies consisting of
antibodies to AdV fiber-knob protein/HA-tag and in combina-
tion with glycocalyx abrogation shown to facilitate AdV entry
into columnar cell-types (44). Similar retargeting has been shown
with chemical conjugation of AdV to receptors via a biotin–
streptavidin “bridge” (41).
Retargeted AdV with fiber-knob protein modified to express
novel ligands that can interact with target receptors have been
developed, and the feasibility of this approach has now been
reported by a number of groups (39, 45).
Strategies to Target Endogenous AdV Receptors
The localization of viral uptake pathways to the basolateral
surfaces of airway epithelial cells suggests that delivery to this
surface could be beneficial for improving gene transfer. Such
an approach may also allow targeting of basal epithelial cell
subpopulations that may function as stem cells for the columnar
epithelium resulting in gene transfer to the lung for the lifetime
of the individual. Targeting stem cells is an important consider-
ation for gene transfer to the airway epithelium because ciliated
cells have a relatively short lifetime (40–90 days), suggesting
that strategies to directly target ciliated cells will require read-
ministration of vectors every 1 to 3 months.
Access to basal cells/basolateral surfaces after intravenous
administration of vectors requires vector dissemination through
the lung blood vessel wall and the surrounding connective tissue,
as well as penetration of the basal lamina underlying the respira-
tory epithelium. Sufficient access to airway epithelial cells via
this route has not yet been demonstrated (46).
An alternative approach to target endogenous AdV receptors
on columnar cells is transient disruption of epithelial tight junc-
tions, thus exposing hCAR, before inoculation by AdV. Walters
and coworkers have shown that treatment of the apical surface
of HAE with the calcium chelator EGTA or hypotonic solutions
(e.g., water) allows for improved AdV-mediated gene transfer
(47). The short-chain fatty acid, sodium caprate, has also been
shown to increase AdV-mediated gene transfer to HAE and
mouse tracheal epithelium in vivo (27, 48). The ability for tight
junctional modulation to potentially allow for AdV access to
basal epithelial stem cells remains to be investigated.
However, even with suitable retargeting strategies for AdV
the requirement of a vector to circumvent the glycocalyx barrier
remains. It is unlikely that effective and safe strategies to abro-
gate the airway glycocalyx sufficient for gene delivery improve-
ment can be developed. Whether further modifications to the
AdV capsid that result in less affinity of the virus for glycocalyx
structures could be achieved has not yet been investigated.
IDENTIFICATION OF OTHER VECTORS THAT
CIRCUMVENT THE PHYSICAL BARRIERS
TO GENE DELIVERY
The focus of this review has been on the use of AdV for use in
treatment strategies for CF lung disease. A number of other
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vectors have been suggested as candidates for CF lung gene
transfer vectors and have been rigorously investigated. Adeno-
associated viruses, retroviruses, lentiviruses, and liposomal vec-
tors have all shown promise in preclinical studies in the lung,
and some have been tested in clinical trials. Although most of
these vectors can be delivered to the human airway epithelium
relatively safely, the efficiency of gene transfer achieved by these
vectors has been low, suggesting that barriers to viral entry
into the target cell types may exist. Strategies to improve gene
transfer efficiency for these other vectors have paralleled the
strategies for improving AdV gene transfer. Whether efficiency
can be improved sufficiently to shows efficacy of gene transfer
in the lungs of patients with CF remains to be determined.
Novel vector types are now being assessed for airway gene
transfer that may be more efficient at breaching airway epithelial
cell barriers. For example, Sendai virus (SeV), the murine equiv-
alent of human parainfluenza virus type 1, has been shown to
infect ciliated and nonciliated cells of rodent airways after intra-
luminal delivery (49). Human coronavirus 229E has been found
to infect human polarized airway epithelia from the apical sur-
face (50), although less than 10% of the cells were infected and
the large size of this viral genome complicates its use as a vector.
HIV-based lentiviral vectors pseudotyped with Ebola virus enve-
lope proteins have been shown to efficiently transduce airway
epithelial cells in vitro and murine airways in vivo (51), suggesting
that combining the efficiency of Ebola virus entry with the poten-
tial longer duration of lentivirus-mediated gene expression may
provide a useful vector for lung gene transfer strategies. In a
similar study, a simian lentiviral vector was pseudotyped with
Sendai virus envelope proteins F and HN, which transduced rat
polarized tracheal epithelial cells in vitro from the apical surface,
albeit with low efficiency (52).
We have recently focused on the paramxyovirus (PV) family
of human respiratory viruses. These viruses are a family of enve-
loped viruses with nonsegmented negative strand RNA ge-
nomes. Human respiratory syncytial virus (RSV) and human
parainfluenza virus (PIV) are, respectively, the first and second
leading causes of viral respiratory disease in infants and children
requiring hospitalization (53). Although most infections are re-
stricted to the upper airways and resolve within 1 to 2 weeks
without treatment, the entire respiratory tract can be infected,
resulting in bronchitis, bronchiolitis, and/or bronchopneumonia,
especially in immunocompromised patients. Almost everyone
has been infected by PV by 2 years of age, but the immunity
induced is typically incomplete and reinfection by the same virus
is common although subsequent infections are partially re-
stricted and the disease severity reduced (53). With regard to
potential gene transfer vectors, it is advantageous that immunity
against PV is incomplete and wanes with time.
The tropism of PV for human respiratory epithelium led us
to test whether RSV efficiently infected HAE and whether any
cell type–specific targeting occurred. The reverse genetics has
enabled the rescue of fully recombinant RSV thus allowing for
viral genome manipulation and insertion of marker transgenes
(54). HAE inoculated with recombinant RSV expressing GFP
showed that RSV efficiently infected columnar epithelial cells
from the apical surface and exclusively infected ciliated epithelial
cells (26). The ability of RSV to transfer genes to the ciliated
cells of the airway epithelium after lumenal delivery suggests
that this virus may provide a new vector system suitable for
disorders of the lung epithelium such as CF lung disease.
RSV infection of respiratory epithelium is however cytotoxic
and pulmonary disease due to RSV infection is caused by both
direct virus-mediated events and the effects of host immune
responses. The most commonly described cytotoxic effect of
RSV infection of non-polarized cells in vitro is giant cell (syncy-
tium) formation, leading to cell death. This effect is likely due
to cell membrane expression of RSV glycoproteins that are fuso-
genic and can interact with neighboring cells to induce cell–cell
fusion (55). However, syncytia formation in respiratory epithe-
lium is rarely encountered in pathological specimens from human
fatal RSV infection, unless individuals are profoundly immuno-
suppressed (53). Indeed our experiments with RSV infection of
HAE did not result in ciliated cell syncytia formation, an effect
likely due trafficking of the fusogenic viral glycoproteins exclu-
sively to the apical surface of ciliated cells where interactions
with neighboring cells would be limited. This conclusion was
supported by the observation that RSV assembled at and budded
exclusively from the apical surface of infected ciliated cells and
spread of virus was propagated by the directional flow of airway
surface liquid dictated by cilia beat direction (26) (Figure 4).
The apical shedding of RSV was not accompanied by gross
cytotoxicity and suggests that RSV spread remains within the
environment of the lung an observation that may explain why
RSV viremia is exceptionally rare. Nevertheless, the cytotoxicity
of replication-competent RSV vectors currently limits their use-
fulness as gene transfer vectors for “proof of concept” studies.
Further study will be required to generate versions of these
vectors that could be used to deliver CFTR to the airway epithe-
lium in vivo. A wide variety of attenuated viruses have been
created and characterized in the development of live attenuated
vaccines against PV (56). Attenuation is defined as a reduced
ability of the virus to cause disease and most commonly reflects a
reduced replication capacity. Replication-attenuated PV vectors
would be desirable for a gene transfer vector. The fact that PV
vaccine candidates can be safety administered to infants and
young children suggests that attenuated PV may be useful for
constructing safer gene transfer vectors (57).
Alternatively, pseudotyped vectors generated using glycopro-
teins from PV (e.g., RSV pseudotyped lentiviral vectors) could
provide vectors that target ciliated cells and have the capacity
to improve duration of transgene expression. However, any strat-
egy to target ciliated cells with CFTR can only “correct” a CF
epithelium for the lifetime of the CFTR-expressing ciliated cells
(40–90 days). Therefore, all vectors directed to ciliated cells,
even integrating vectors, will ultimately require repeat adminis-
tration. In the absence of an identified stem cell for ciliated cells
and a suitable vector that can target such a stem cell, the repeat
dosing of vectors that target ciliated cells that are safe and can
be readministered every 2 to 3 months is an acceptable strategy
at the present time.
CONCLUSIONS
A gene transfer strategy for the treatment of CF lung disease
still struggles to prove itself as a realistic goal, not least because
the immature science of in vivo gene transfer was referred to at
the outset as “gene therapy.” The promise of a gene therapy set
unrealistic goals for this approach, for as we have discovered,
there are multiple barriers to achieving efficacious and safe deliv-
ery of genes to the lung, of which only a few have been discussed
here. The field of in vivo gene transfer has been aided by many
different aspects of basic biological and medical research efforts
and the eventual realization of a gene therapy for CF lung disease
will only take time and a continuation of these efforts.
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